Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Selective lymph node dissection for castration-resistant prostate cancer.

Busch J, Hinz S, Kempkensteffen C, Erber B, Klopf C, Weikert S, Miller K, Magheli A.

Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7.

PMID:
22398510
2.

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F.

Eur Urol. 2011 Nov;60(5):935-43. doi: 10.1016/j.eururo.2011.07.060. Epub 2011 Aug 3.

PMID:
21840116
3.

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.

Eur Urol. 2015 Feb;67(2):299-309. doi: 10.1016/j.eururo.2014.02.011. Epub 2014 Feb 18.

PMID:
24571959
4.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
5.

The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.

DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.

J Urol. 2005 Apr;173(4):1121-5.

PMID:
15758719
6.
7.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.

Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.

BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.

8.

Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.

Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM.

Urology. 2007 Oct;70(4):723-7.

PMID:
17991544
9.
10.

Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.

Godoy G, Chong KT, Cronin A, Vickers A, Laudone V, Touijer K, Guillonneau B, Eastham JA, Scardino PT, Coleman JA.

Eur Urol. 2011 Aug;60(2):195-201. doi: 10.1016/j.eururo.2011.01.016. Epub 2011 Jan 18.

PMID:
21257258
12.

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.

Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML.

Eur Urol. 2009 Feb;55(2):261-70. doi: 10.1016/j.eururo.2008.09.043. Epub 2008 Oct 1.

PMID:
18838212
14.

Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.

Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.

PMID:
15708249
15.

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.

Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.

J Urol. 2007 Sep;178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16.

PMID:
17631342
16.

Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.

Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL.

Int J Radiat Oncol Biol Phys. 1998 Jul 1;41(4):735-40.

PMID:
9652832
17.

Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.

Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC.

J Urol. 2004 Nov;172(5 Pt 1):1860-4.

PMID:
15540739
18.

Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.

Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG.

J Urol. 1999 Apr;161(4):1233-7.

PMID:
10081876
19.

Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?

King CR, Presti JC Jr, Gill H, Brooks J, Hancock SL.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):341-7.

PMID:
15145146
20.

Risk of prostate carcinoma death in patients with lymph node metastasis.

Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG.

Cancer. 2001 Jan 1;91(1):66-73.

PMID:
11148561
Items per page

Supplemental Content

Write to the Help Desk